TEVA icon

Teva Pharmaceuticals

16.94 USD
At close May 16, 4:00 PM EDT
After hours
16.71
-0.23
1.36%
1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
43.93%
10 years
-71.86%
 

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 35,686

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

109% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 45

81% more call options, than puts

Call options by funds: $727M | Put options by funds: $402M

31% more capital invested

Capital invested by funds: $11.2B [Q3] → $14.7B (+$3.43B) [Q4]

29% more funds holding in top 10

Funds holding in top 10: 28 [Q3] → 36 (+8) [Q4]

7% more funds holding

Funds holding: 533 [Q3] → 568 (+35) [Q4]

2.7% more ownership

Funds ownership: 55.99% [Q3] → 58.69% (+2.7%) [Q4]

2% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 187

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
30%
upside
Avg. target
$23
33%
upside
High target
$23
36%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
JP Morgan
Chris Schott
41% 1-year accuracy
7 / 17 met price target
36%upside
$23
Overweight
Upgraded
12 May 2025
B of A Securities
Jason Gerberry
35% 1-year accuracy
7 / 20 met price target
30%upside
$22
Buy
Maintained
8 May 2025

Financial journalist opinion

Based on 20 articles about TEVA published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company's branded franchises, stabilization of the company's generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085.
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
Positive
The Motley Fool
4 days ago
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (TEVA 5.82%) well higher on Monday. The company, known for being a top producer of generic drugs, saw its share price swell almost 6% as a result.
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
Positive
Seeking Alpha
1 week ago
Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside
Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Recent FDA wins, like SELARSDI, show Teva's pushing into high-margin markets.
Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside
Neutral
Zacks Investment Research
1 week ago
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
Positive
The Motley Fool
1 week ago
Why Teva Pharmaceutical Stock Is Soaring Today
Shares of Teva Pharmaceutical (TEVA 8.44%) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m.
Why Teva Pharmaceutical Stock Is Soaring Today
Positive
Barrons
1 week ago
Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says
The drugmaker reported first-quarter earnings that beat expectations and raised its full-year guidance.
Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says
Positive
Benzinga
1 week ago
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first-quarter 2025 financial results. Here are the details.
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
Positive
CNBC Television
1 week ago
Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more.
Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties
Positive
Proactive Investors
1 week ago
Teva Pharma climbs as earnings impress
Shares in Teva Pharmaceutical Industries (NASDAQ:TEVA) rose 5% after publishing first-quarter earnings, where the Israeli company said US tariffs are expected to have an "immaterial impact".  The Tel Aviv-based drugs maker reported revenue of $3.9 billion for the quarter, a 5% increase in local currency terms as key growth products continued to perform well, with operating income swinging to $519 million from a loss of $218 million a year ago.
Teva Pharma climbs as earnings impress
Neutral
Seeking Alpha
1 week ago
Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2025 Earnings Call May 7, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric A. Hughes - EVP, Global R&D and Chief Medical Officer Eli Kalif - EVP & CFO Conference Call Participants David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Ashwani Verma - UBS Investment Bank Christopher Schott - J.P.
Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript
Charts implemented using Lightweight Charts™